Consensus document from GESITRA-SEIMC on the prevention and treatment of cytomegalovirus in transplanted patients;Recomendaciones GESITRA-SEIMC y RESITRA sobre prevención y tratamiento de la infección por citomegalovirus en pacientes trasplantados

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue 7, 2005, Pages 424-437

  Torre Cisneros, Julián ^a,b   Fortún, Jesús ^b,c   Aguado, José Maria ^b,d   De La Cámara, Rafael ^e   Cisneros, José Miguel ^b,f   Gavaldá, Joan ^b,g   Gurguí, Mercé ^b,h   Lumbreras, Carlos ^b,d   Martín, Carmen ^a   Martín Dávila, Pilar ^b,c   Montejo, Miguel ^b,i   Monero, Asunción ^b,j   Muñoz, Patricia ^b,k   Pahissa, Albert ^b,g   Pérez, José Luis ^b,l   Rovira, Montserrat ^j   Bernardos, Ángel ^f   Gil Vernet, Salvador ^m   Quijano, Yolanda ⁿ   Rábago, Gregorio ^o   Román, Antoni ^g   Varó, Evaristo ^p   more..

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica Madrid   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ HOSPITAL DE CRUCES   (Spain)

^j HOSPITAL CLÍNIC   (Spain)

^k HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^l HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^m HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁿ Montepríncipe University Hospital   (Spain)

^o UNIVERSITY CLINIC OF NAVARRA   (Spain)

^p HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

more..

Author keywords

Cytomegalovirus; Guidelines; Prevention; Transplant

Indexed keywords

ACICLOVIR; ADEFOVIR; ANTIVIRUS AGENT; BENZIMIDAVIR; BENZIMIDAZOLE; CIDOFOVIR; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; LEFLUNOMIDE; LOBUCAVIR; VALACICLOVIR; VALGANCICLOVIR;

CONSENSUS DEVELOPMENT; CYTOMEGALOVIRUS INFECTION; HUMAN; ORGAN TRANSPLANTATION; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PROPHYLAXIS; REVIEW; RISK FACTOR;

EID: 25844486486     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13078802     Document Type: Article

References (105)

1. Kish MA. Guide to development of practice guidelines. Clin Infect Dis. 2001;32:851-4.
2. Ljungman P, Griffths P, Paya C. Definitions of Cytomegalovirus Infection and Disease in Transplant Recipients. Clin Infect Dis. 2002;34:1094-7.
3. Anónimo. Comparison and availability of diagnostic assays for cytomegalovirus detection in transplant recipients. En: Griffiths PD, Whitley RJ, editors. The challenge of CMV infection and disease in transplantation. Reccomendations from the IHMF Management Strategies Workshop and the 8th Annual Meeting of the IHMF. Disponible en: http://www.ihmf.org
4. Kalpoe JS, Kroes AC, De Jong MD, Schinkel J, De Brouwer CS, Beersma MF, et al. Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of criteria by analysis of correlation to antigen detection. J Clin Microbiol. 2004;42:1498-504.
5. Martín-Dávila P, Fortún J, Gutiérrez C, Martí-Belda P, Candelas A, Honrubia A, et al. Analysis of a quantitative PCR assay for CMV infection in liver transplant recipients: an intent to find the optimal cut-off value. J Clin Virol. En prensa 2005.
6. Niubo J, Pérez JL, Martínez-Lacasa JT, Garcia A, Roca J, Fabregat J, et al. Association of quantitative cytomegalovirus antigenemia with symptomatic infection in solid organ transplant patients. Diagn Microbiol Infect Dis. 1996;24:19-24.
7. Pang XL, Chui L, Fenton J, LeBlanc B, Preiksaitis JK. Comparison of the LyghtCycler-based PCR, Cobas Amplicor CMV Monitor, and pp 65 antigenemia assays for quantitative measurement of cytomegalovirus viral load in peripheral blood specimens from patients after solid organ transplantation. J Clin Microbiol. 2003;41:3167-74.
8. Razonable RR, Paya CV, Smith TF. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol. 2002;40:746-52.
9. Meyer-Koenig U, Weidmann M, Kirste G, Hufert FT. Cytomegalovirus infection in organ-transplant recipients: diagnostic value of pp65 antigen test, qualitative polymerase chain reaction (PCR) and quantitative Taqman PCR. Transplantation. 2004;77:1692-8.
10. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986;153:478-88.
11. Matthes-Martin S, Lion T, Aberle SW, Fritsch G, Lawitschka A, Bittner B, et al. Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serotatus on the incidence of CMV disease and CMV-related mortality. Bone Marrow Transplant. 2003;31:803-8.
12. Meijer E, Dekker AW, Rozenberg-Arska M, Weersink AJ, Verdonck LF. Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related an unrelated donors. Clin Infect Dis. 2002;35:703-12.
13. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood. 2003;102:4255-60.
14. Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley J, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood. 2001;97:1232-40.
15. Quinnan GV Jr, Kirmani N, Rook AH, Manischewitz JF, Jackson L, Moreschi G, et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982;307:7-13.
16. Yanada M, Yamamoto K, Emi N, Naoe T, Suzuki R, Taji H, et al. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;32:801-7.
17. Reusser P, Fisher LD, Buckner CD, Thomas ED, Meyers JD. Cytomegalovirus infection after autologous bone marrow transplantation: ocurrence of cytomegalovirus disease and effect on engraftment. Blood 1990;75: 1888-994.
18. Hebart H, Brugger W, Grigoleit U, Gscheidle B, Loeffler J, Schafer H, et al. Risk of cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality. Blood. 2001;97:2183-5.
19. Emery VC, Sabin CA, Cope AV, Go D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet. 2003;355:2032-6.
20. Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991;78:246-50.
21. Ljungman P, Reusser P, De la Cámara R, Einsele H, Engelhard D, Ribaud P, et al, Cordonnier C for the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantat. 2004;33:1075-81.
22. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR Morb Mortal Wkly Rep. 2000;49(RR-10):1-125.
23. Einsele H, Reusser P, Hertenstein B. Pharmacokinetics of oral valganciclovir versus FV ganciclovir for CMV pre-emptive therapy in SCT. Bone Marrow Transplant. 2004;33 Suppl 1:abstract 272;S41.
24. Mattes FM, Hainsworth EG, Geretti AM, Nebbia G, Prentice G, Potter M, et al. A randomized, Controlled Trial Comparing Ganciclovir to Ganciclovir Plus Foscarnet (Each at Half Dose) for Preemptive Therapy of Cytomegalovirus Infection in Transplant Recipients. J Infec Dis. 2004;189:1355-61.
25. Rubin R. Infection in the organ transplant recipient. En: Rubin Rh YL, editor. Clinical approach to infection in the compromised host. New York: Kluver Academic/Plenum Publishers; 2002. p. 573-679.
26. Paya C, Razonable RR. Cytomegalovirus infection after solid organ transplantation. En: Bowden RA, Ljungman P, Paya CV, editors. Transplant Infections. 2nd ed. Philadelphia: Lippincott Williams and Wilkins; 2003. p. 298-325.
27. Emery VC, Hassan-Walker AF, Burroughs AK, Griffiths PD. Cytomegalovirus (CMV) replication dynamics in CMV-naive and experienced immunocompromised hosts. J Infect Dis. 2002;185:1723-8.
28. Falagas ME, Snydman DR, George MJ, Werner B, Ruthazer R, Griffith J, et al. Incidence and predictor of CMV pneumonia in orthotopic liver transplant recipients. Transplantation. 1996;62:1716-20.
29. Kirklin JK, Naftel DC, Levine TB, Bourge RC, Pelletier GB, O'Donnell J, et al. CMV after heart transplantation. Risk factors for infection and death: a multiinstitutional study. J Heart Lung Transplant 1994;13:394-404.
30. Calhoon JH, Nichols L, Davis R, Bryant CL, Levine SM, Zamora CA. Single lung transplantation. Factors in postoperative cytomegalovirus infection. J Thorac Cardiovasc Surg. 1992;103:21-5.
31. Manez R, Kusne S, Green M, Abu-Elmagd K, Irish W, Reyes J, et al. Incidence and risk factors associated with the development of CMV disease after intestinal transplantation. Transplantation. 1995;59:1010-4.
32. Kaufman DB, Leventhal JR, Gallon LG, Parker MA, Koffron AJ, Fryer JP, et al. Risk factors and impact of CMV disease in simultaneous pancreas-kidney transplantation. Transplantation. 2001;72:1940-5.
33. Fietze E, Prosch S, Reinke P, Stein J, Docke WD, Staffa G, et al. Cytomegalovirus infection in transplant recipients: the role of tumor necrosis factor. Transplantation. 1994;58:675-80.
34. Docke WD, Prosch S, Fietze E, Kimel V, Zuckermann H, Klug C, et al. Cytomegalovirus reactivation and tumour necrosis factor. Lancet. 1994;343: 268-9.
35. Bernabeu-Wittel M, Naranjo M, Cisneros JM, Canas E, Gentil MA, Algarra G, et al. Infections in renal transplant recipients receiving mycophenolate versus azathioprine-based immunosupression. Eur J Clin Microbiol Infec Dis. 2002;21:173-80.
36. Chemaly RF, Yen-Lieberman B, Castilla EA, Reilly A, Arrigain S, Farver C, et al. Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry.J Clin Microbiol. 2004;42:2168-72.
37. DesJardin JA, Cho E, Supran S, Gibbons L, Werner BG, Snydman DR. Association of human herpesvirus 6 reactivation with severe cytomegalovirus- associated disease in orthotopic liver transplant recipients. Clin Infect Dis. 2001;33:1358-62.
38. Saliba F, Arulnaden JL, Gugenheim J, Serves C, Samuel D, Bismuth A, et al. CMV hyperimmune globulin prophylaxis after liver transplantation: a prospective randomized controlled study. Transplant Proc. 1989;21:2260-2.
39. Snydman DR, Werner BG, Dougherty NN, Griffith J, Rubin RH, Dienstag JL, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized, double-blind, placebo-controlled trial. The Boston Center for Liver Transplantation CMVIG Study Group. Ann Intern Med. 1993;119:984-91.
40. Valantine HA, Luikart H, Doyle R, Theodore J, Hunt S, Oyer P, et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation. 2001;72:1647-52.
41. Bonaros NE, Kocher A, Dunkler D, Grimm M, Zuckermann A, Ankersmit J, et al. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. Transplantation. 2004;77:890-7.
42. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med. 1999;340: 1462-70.
43. Akalin E, Sehgal V, Ames S, Hossain S, Daly L, Barbara M, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant. 2003;3:731-5.
44. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611-20.
45. Conti DJ, Freed BM, Singh TP, Gallichio M, Gruber SA, Lempert N. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients. Arch Surg. 1995;130:1217-21.
46. Hibberd PL, Tolkoff-Rubin NE, Conti D, Stuart F, Thistlethwaite JR, Neylan JF, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med. 1995;123:18-26.
47. Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, et al. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation. 1998;66:1682-8.
48. Sagedal S, Nordal KP, Hartmann A, Midtvedt K, Foss A, Asberg A, et al. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrol Dial Transplant. 2003;18:1899-908.
49. Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, et al. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet. 1997;350: 1729-33.
50. Erratum in: Lancet. 1998;351:454.
51. Barkholt L, Lewensohn-Fuchs I, Ericzon BG, Tyden G, Andersson J. High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients. Transplant Infect Dis. 1999;1:89-97.
52. Badley AD, Seaberg EC, Porayko MK, Wiesner RH, Keating MR, Wilhelm MP, et al. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. Transplantation. 1997;64:66-73.
53. Winston DJ, Busutil RW. Ranzomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Trasplantation. 2003;75:229-33.
54. Winston DJ, Busutil RW. Ranzomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalo-virus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Trasplantation. 2004;77:305-8.
55. FDA, safety information, VALCYTE (valgancyclovir HCI tablets), (http:// www.fda.gov/medwatch/SAFETY/2003/valcyte.htm
56. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial. Transplantation. 2000;70:717-22.
57. Torre-Cisneros J, Madueno JA, Herrero C, De la Mata M, González R, Rivero A, et al. Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients. Clin Microbiol Infect. 2002;8: 773-80.
58. Paya CV. Prevention of cytomegalovirus disease in recipients of solid-organ transplants. Clin Infect Dis. 2001;32:596-603.
59. Macdonald PS, Keogh AM, Marshman D, Richens D, Harvison A, Kaan AM, et al. A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation. J Heart Lung Transplant. 1995;14(1 Pt 1):32-8.
60. Merigan TC, Renlund DG, Keay S, Bristow MR, Starnes V, O'Connell JB, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med. 1992;326:1182-6.
61. Aguado JM, Gómez-Sánchez MA, Lumbreras C, Delgado J, Lizasoain M, Otero JR, et al. Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3. Antimicrob Agents Chemother. 1995;39:1643-5.
62. Valenza M, Czer LS, Pan SH, Aleksic I, Freimark D, Harasty DA, et al. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation. J Heart Lung Transplant. 1995;14:659-65.
63. Vrtovec B, Thomas CD, Radovancevic R, Frazier OH, Radovancevic B. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients. J Heart Lung Transplant. 2004;23:461-5.
64. Egan JJ, Lomax J, Barber L, Lok SS, Martyszczuk R, Yonan N, et al. Pre-emptive treatment for the prevention of cytomegalovirus disease: in lung and heart transplant recipients. Transplantation. 1998;65:747-52.
65. Senechal M, Dorent R, Du Montcel ST, Fillet AM, Ghossoub JJ, Dubois M, et al. Monitoring of human cytomegalovirus infections in heart transplant recipients by pp65 antigenemia. Clin Transplant. 2003;17:423-7.
66. Casillo R, Grimaldi M, Ragone E, Maiello C, Marra C, De Santo L, et al. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients. Transplant Proc. 2004;36:651-3.
67. Devyatko E, Zuckermann A, Ruzicka M, Bohdjalian A, Wieselthaler G, Rodler S, et al. Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation. J Heart Lung Transplant. 2004;23:1277-82.
68. Wreghitt T. Cytomegalovirus infections in heart and heart-lung transplant recipients. J Antimicrob Chemother. 1989;23:4960.
69. Soghikian MV, Valentine VG, Berry GJ, Patel HR, Robbins RC, Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant. 1996;15:881-7.
70. Hertz MI, Jordan C, Savik SK, Fox JM, Park S, Bolman RM 3rd, et al. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. J Heart Lung Transplant. 1998;17:913-20.
71. Bhorade SM, Sandesara C, Garrity ER, Vigneswaran WT, Norwick L, Alkan S, et al. Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients. J Heart Lung Transplant. 2001;20:928-34.
72. Gavalda J, Román A, Guerra F, Monforte V, Bravo C, Calico I, et al. Is oral ganciclovir less effective than IV Ganciclovir in the prophylaxis of CMV disease in lung transplant patients (LPt)? Abstract: V-1247. 42nd ICAAC Abstracts, American Society for Microbiology, September 27-30, 2002, San Diego, CA, p. 439.
73. Zamora MR, Nicolls MR, Hodges TN, Marquesen J, Astor T, Grazia T, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant. 2004;4:1635-42.
74. Maurer JR, Snell G, De Hoyos A, Kesten S, Winton T. Outcomes of lung transplantation using three different cytomegalovirus prophylactic regimens. Transplant Proc. 1993;25:1434-5.
75. Gould FK, Freeman R, Taylor CE, Ashcroft T, Dark JH, Corris PA. Prophylaxis and management of cytomegalovirus pneumonitis after lung transplantation: a review of experience in one center. J Heart Lung Transplant. 1993;12:695-9.
76. Kruger RM, Paranjothi S, Storch GA, Lynch JP, Trulock EP. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients. J Heart Lung Transplant. 2003;22:754-63.
77. Weill D, Lock BJ, Wewers DL, Young KR, Zorn GL, Early L, et al. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction. Am J Transplant. 2003;3:492-6.
78. Egan JJ, Barber L, Lomax J, Fox A, Yonan N, Rahman AN, et al. Detection of human cytomegalovirus antigenemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients. Thorax. 1995;50:9-13.
79. Kelly J, Hurley D, Raghu G. Comparison of the efficacy and cost effectiveness of preemptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. J Heart Lung Transplant. 2000;19:355-9.
80. Lumbreras C, Fernández I, Velosa J, Munn S, Sterioff S, Paya CV. Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome. Clin Infect Dis. 1995;20:514-20.
81. Smets YF, Van der Fiji JW, Van Dissel JT, Ringers J, De Fijter JW, Lemkes HH. Infectious disease complications of simultaneous pancreas kidney transplantation. Nephrol Dial Transplant. 1997;12:764-71.
82. Hopt UT, Pfeffer F, Schareck W, Busing M, Ming C. Ganciclovir for prophylaxis of CMV disease after pancreas/kidney transplantation. Transplant Proc. 1994;26:434-5.
83. Nalesnik M, Jaffe R, Reyes J, Mazariegos G, Fung JJ, Starzl TE, et al. Post-transplant lymphoproliferative disorders in small bowel allograft recipients. Transplant Proc. 2000;32:1213.
84. Reyes J, Green M, Bueno J, Jabbour N, Nalesnik M, Yunis E, et al. Epstein-Barr virus associated posttransplant lymphoproliferative disease after intestine transplantation. Transplant Proc. 1996;28:2768-9.
85. Burroughs M, Sobanjo A, Florman S, Kaufman SS, Fishbein T. Cytomegalovirus matching does not predict symptomatic disease in intestinal transplantation. Transplant Proc. 2002;34:946-7.
86. Tzakis AG. Cytomegalovirus prophylaxis with ganciclovir and cytomegalo-virus immune globulin in liver and intestinal transplantation. Transpl Infect Dis. 2001;3 Supl 2:35-9.
87. Forman SJ, Zaia JA. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? Blood. 1994;83:2392-8.
88. Ljungman P, Deliliers GL, Platzbecker U, Matthes-Martin S, Bacigalupo A, Einsele H, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. Blood. 2001;97:388-92.
89. Vitravene Study Group. Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am J Ophthalmol. 2002;133:475-83.
90. Hebart H, Kanz L, Jahn G, Einsele H. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current Guidelines and Future Prospects. Drugs. 1998;55:59-72.
91. Fishman JA, Rubin RH. Infection in organ transplant recipients. N Engl J Med. 1998;338:1741-51.
92. Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002;346:1119-26.
93. Babel N, Gabdrakhmanova L, Juergensen JS, Eibl N, Hoerstrup J, Hammer M, et al. Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: A single center experience. Transplantation. 2004;78:283-5.
94. Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: a randomized, controlled trial. Ann Intern Med. 1997; 126:257-63.
95. John GT, Manivannan J, Chandy S, Peter S, Jacob CK. Leflunomide therapy for cytomegalovirus disease in renal allograft recipients. Transplantation. 2004;77:1460-1.
96. Zou R, Drach JC, Townsend B. Design, syntesis, and antiviral evaluation of 2-chloro-5,6-dihalo-1-beta-d-ribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections. J Med Chem. 1997;40:811-8.
97. Xiong X, Flores C, Fuller MD, Mendel DB, Mulato AS, Moon K, et al. In vitro characterization of the anti-human cytomegalovirus activity of PMEA (adefovir). Antiviral Res. 1997;36:131-7.
98. Tenney DJ, Yamanaka G, Voss SM, Cianci CW, Tuomari AV, Sheaffer AK, et al. Lobucavir is phosphorylated in human cytomegalovirus infected and uninfected cells and inhibits the viral DNA polymerase. Antimicrob Agents Chemother. 1997;41:2680-5.
99. Lu H, Thomas S. Maribavir (ViroPharma). Curr Opin Investig Drugs. 2004;5:898-906.
100. Manischewitz JF, Quinnan GV, Lane HC, Wittek AE. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1990;34:373-5.
101. Mylonakis E, Kallas WM, Fishman JA. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis. 2002;34:1337-41.
102. Kruger RM, Shannon WD, Arens MQ, Lynch JP, Storch GA, Trulock EP. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation. 1999;68:1272-9.
103. Manion DJ, Vibhagool A, Chou TC, Kaplan J, Caliendo A, Hirsch MS. Susceptibility of human cytomegalovirus to two-drug combinations in vitro. Antivir Ther. 1996;1:237-45.
104. Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis. 1997;176:69-77.
105. Van der Bij W, Speich R. Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin Infect Dis. 2001;33 Supl 1:S33-S37.